Literature DB >> 25663168

Absence of CCL2 and CCL3 Ameliorates Central Nervous System Grey Matter But Not White Matter Demyelination in the Presence of an Intact Blood-Brain Barrier.

Katharina Janssen1, Mira Rickert1, Tim Clarner1, Cordian Beyer1, Markus Kipp2,3.   

Abstract

A broad spectrum of diseases is characterized by myelin abnormalities, oligodendrocyte pathology, and concomitant glia activation, among multiple sclerosis (MS). Our knowledge regarding the factors triggering gliosis and demyelination is scanty. Chemokines are pivotal for microglia and astrocyte activation and orchestrate critical steps during the formation of central nervous system (CNS) demyelinating lesions. Redundant functions of chemokines complicate, however, the study of their functional relevance. We used the cuprizone model to study redundant functions of two chemokines, CCL2/MCP1 and CCL3/MIP1α, which are critically involved in the pathological process of cuprizone-induced demyelination. First, we generated a mutant mouse strain lacking functional genes of both chemokines and demonstrated that double-mutant animals are viable, fertile, and do not present with gross abnormalities. Astrocytes and peritoneal macrophages, cultured form tissues of these animals did neither express CCL2 nor CCL3. Exposure to cuprizone resulted in increased CCL2 and CCL3 brain levels in wild-type but not mutant animals. Cuprizone-induced demyelination, oligodendrocyte loss, and astrogliosis were significantly ameliorated in the cortex but not corpus callosum of chemokine-deficient animals. In summary, we provide a novel powerful model to study the redundant function of two important chemokines. Our study reveals that chemokine function in the CNS redounds to region-specific pathophysiological events.

Entities:  

Keywords:  CNS; Chemokines; Cuprizone; Multiple sclerosis

Mesh:

Substances:

Year:  2015        PMID: 25663168     DOI: 10.1007/s12035-015-9113-6

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  87 in total

1.  Immunopathology of secondary-progressive multiple sclerosis.

Authors:  J W Prineas; E E Kwon; E S Cho; L R Sharer; M H Barnett; E L Oleszak; B Hoffman; B P Morgan
Journal:  Ann Neurol       Date:  2001-11       Impact factor: 10.422

2.  Functional expression of CCR2 by human fetal astrocytes.

Authors:  Anuska V Andjelkovic; Li Song; Kirk A Dzenko; Hui Cong; Joel S Pachter
Journal:  J Neurosci Res       Date:  2002-10-15       Impact factor: 4.164

3.  Impact of peripheral levels of chemokines, BDNF and oxidative markers on cognition in individuals with schizophrenia.

Authors:  Elson Asevedo; Ary Gadelha; Cristiano Noto; Rodrigo B Mansur; André Zugman; Síntia I N Belangero; Arthur A Berberian; Bruno S Scarpato; Emilie Leclerc; Antônio L Teixeira; Clarissa S Gama; Rodrigo A Bressan; Elisa Brietzke
Journal:  J Psychiatr Res       Date:  2013-06-25       Impact factor: 4.791

Review 4.  Multiple sclerosis pathology: evolution of pathogenetic concepts.

Authors:  Hans Lassmann
Journal:  Brain Pathol       Date:  2005-07       Impact factor: 6.508

5.  Corticosteroids impair remyelination in the corpus callosum of cuprizone-treated mice.

Authors:  T Clarner; A Parabucki; C Beyer; M Kipp
Journal:  J Neuroendocrinol       Date:  2011-07       Impact factor: 3.627

Review 6.  Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.

Authors:  Adam Szczuciński; Jacek Losy
Journal:  Acta Neurol Scand       Date:  2007-03       Impact factor: 3.209

7.  Characterization and distribution of phagocytic macrophages in multiple sclerosis plaques.

Authors:  H Li; J Newcombe; N P Groome; M L Cuzner
Journal:  Neuropathol Appl Neurobiol       Date:  1993-06       Impact factor: 8.090

8.  Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant.

Authors:  J C Lorentzen; S Issazadeh; M Storch; M I Mustafa; H Lassman; C Linington; L Klareskog; T Olsson
Journal:  J Neuroimmunol       Date:  1995-12-31       Impact factor: 3.478

9.  Experimental autoimmune encephalomyelitis (EAE) in CCR2(-/-) mice: susceptibility in multiple strains.

Authors:  Stefanie Gaupp; David Pitt; William A Kuziel; Barbara Cannella; Cedric S Raine
Journal:  Am J Pathol       Date:  2003-01       Impact factor: 4.307

10.  Pathoetiology of multiple sclerosis: are we barking up the wrong tree?

Authors:  Peter K Stys
Journal:  F1000Prime Rep       Date:  2013-06-03
View more
  14 in total

1.  IL-17 induces MIP-1α expression in primary mouse astrocytes via TRPC channel.

Authors:  Yuan Zhang; Rongrong Huang; Yanhong Zhang; Hongwei Yi; Ying Bai; Jie Chao; Honghong Yao
Journal:  Inflammopharmacology       Date:  2016-01-19       Impact factor: 4.473

2.  Reboxetine Treatment Reduces Neuroinflammation and Neurodegeneration in the 5xFAD Mouse Model of Alzheimer's Disease: Role of CCL2.

Authors:  Irene L Gutiérrez; Marta González-Prieto; Javier R Caso; Borja García-Bueno; Juan C Leza; José L M Madrigal
Journal:  Mol Neurobiol       Date:  2019-07-11       Impact factor: 5.590

3.  Toll-Like Receptor 2-Mediated Glial Cell Activation in a Mouse Model of Cuprizone-Induced Demyelination.

Authors:  Stefan Esser; Larissa Göpfrich; Kai Bihler; Eugenia Kress; Stella Nyamoya; Simone C Tauber; Tim Clarner; Matthias B Stope; Thomas Pufe; Markus Kipp; Lars-Ove Brandenburg
Journal:  Mol Neurobiol       Date:  2017-12-29       Impact factor: 5.590

4.  Cuprizone feeding induces swollen astrocyte endfeet.

Authors:  Petra Fallier-Becker; Irina Bonzheim; Friederike Pfeiffer
Journal:  Pflugers Arch       Date:  2022-10-15       Impact factor: 4.458

5.  Significant higher-level C-C motif chemokine ligand 2/3 and chemotactic power in cerebral white matter than grey matter in rat and human.

Authors:  Jingdong Zhang; Xinrui Gong; Huangui Xiong
Journal:  Eur J Neurosci       Date:  2021-03-16       Impact factor: 3.698

6.  Brain region-specific enhancement of remyelination and prevention of demyelination by the CSF1R kinase inhibitor BLZ945.

Authors:  Nicolau Beckmann; Elisa Giorgetti; Anna Neuhaus; Stefan Zurbruegg; Nathalie Accart; Paul Smith; Julien Perdoux; Ludovic Perrot; Mark Nash; Sandrine Desrayaud; Peter Wipfli; Wilfried Frieauff; Derya R Shimshek
Journal:  Acta Neuropathol Commun       Date:  2018-02-15       Impact factor: 7.801

Review 7.  Brain vascular heterogeneity: implications for disease pathogenesis and design of in vitro blood-brain barrier models.

Authors:  Midrelle E Noumbissi; Bianca Galasso; Monique F Stins
Journal:  Fluids Barriers CNS       Date:  2018-04-23

Review 8.  Macroglial diversity: white and grey areas and relevance to remyelination.

Authors:  Inge L Werkman; Dennis H Lentferink; Wia Baron
Journal:  Cell Mol Life Sci       Date:  2020-07-09       Impact factor: 9.261

Review 9.  The role of chemokines and chemokine receptors in multiple sclerosis.

Authors:  Li-Yuan Cui; Shi-Feng Chu; Nai-Hong Chen
Journal:  Int Immunopharmacol       Date:  2020-03-18       Impact factor: 4.932

10.  CCL3 contributes to secondary damage after spinal cord injury.

Authors:  Nicolas Pelisch; Jose Rosas Almanza; Kyle E Stehlik; Brandy V Aperi; Antje Kroner
Journal:  J Neuroinflammation       Date:  2020-11-27       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.